Literature DB >> 23293198

Impact of the severity of end-stage liver disease in cardiac structure and function.

Odilson Marcos Silvestre1, Fernando Bacal, Danusa de Souza Ramos, Jose L Andrade, Meive Furtado, Vincenzo Pugliese, Elisangela Belleti, Wellington Andraus, Flair José Carrilho, Luiz Augusto Carneiro D'Albuquerque, Alberto Queiroz Farias.   

Abstract

BACKGROUND: The impact of end-stage liver disease (ESLD) in cardiac remodeling of patients with cirrhosis is unknown. Our aim was to correlate the severity of ESLD with morphologic and functional heart changes.
MATERIAL AND METHODS: 184 patients underwent a protocol providing data on the severity of ESLD and undergoing echocardiography to assess the diameters of the left atrium and right ventricle; the systolic and diastolic diameters of the left ventricle, interventricular septum, and posterior wall of the left ventricle; systolic pulmonary artery pressure; ejection fraction; and diastolic function. Severity of ESLD was assessed by the Model for End-Stage Liver Disease (MELD) score.
RESULTS: Left-atrial diameter (r = 0.323; IC 95% 0.190-0.455; p < 0.001), left-ventricular diastolic diameter (r = 0.177; IC 95% 0.033-0.320; p = 0.01) and systolic pulmonary artery pressure (r = 0.185; IC 95% 0.036-0.335; p = 0.02) significantly correlated with MELD score. Patients with MELD ≥ 16 had significantly higher left-atrial diameter and systolic pulmonary artery pressure, compared with patients with MELD scores < 16 points.
CONCLUSIONS: Changes in cardiac structure and function correlate with the severity of ESLD.

Entities:  

Mesh:

Year:  2013        PMID: 23293198

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  8 in total

1.  Cirrhosis-related changes in left ventricular function and correlation with the model for end-stage liver disease score.

Authors:  Xiaopeng Li; Shanshan Yu; Lu Li; Donggang Han; Shejiao Dai; Ya Gao
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  Specific Etiologies Associated With the Multiple Organ Dysfunction Syndrome in Children: Part 2.

Authors:  Jeffrey S Upperman; John C Bucuvalas; Felicia N Williams; Bruce A Cairns; Charles S Cox; Allan Doctor; Robert F Tamburro
Journal:  Pediatr Crit Care Med       Date:  2017-03       Impact factor: 3.624

3.  Correlation of Serum Cardiac Markers with Acute Decompensating Events in Liver Cirrhosis.

Authors:  Miaomiao Li; Zeqi Guo; Dan Zhang; Xiangbo Xu; Fernando Gomes Romeiro; Andrea Mancuso; Jingqiao Zhang; Ruirui Feng; Xinmiao Zhou; Cen Hong; Xingshun Qi
Journal:  Gastroenterol Res Pract       Date:  2020-09-24       Impact factor: 2.260

4.  Cardiohepatic interactions--from humoral theory to organ transplantation.

Authors:  Odilson Marcos Silvestre; Fernando Bacal; Rafael Oliveira Ximenes; Flair José Carrilho; Luiz Augusto Carneiro D'Albuquerque; Alberto Queiroz Farias
Journal:  Arq Bras Cardiol       Date:  2014-06       Impact factor: 2.000

5.  Impact of cytokine release on ventricular function after hepatic reperfusion: a prospective observational echocardiographic study with tissue Doppler imaging.

Authors:  Marco P Zalunardo; Martin Schläpfer; Beatrice Beck-Schimmer; Burkhardt Seifert; Donat R Spahn; Dominique Bettex
Journal:  BMC Anesthesiol       Date:  2015-07-25       Impact factor: 2.217

6.  Cirrhotic cardiomyopathy: is there any correlation between the stage of cardiac impairment and the severity of liver disease?

Authors:  Rania Hammami; Mouna Boudabbous; Jihen Jdidi; Fatma Trabelsi; Fakher Mroua; Rahma Kallel; Ali Amouri; Dorra Abid; Nabil Tahri; Leila Abid; Samir Kammoun
Journal:  Libyan J Med       Date:  2017-12       Impact factor: 1.657

Review 7.  Cardiac Imaging in Liver Transplantation Candidates: Current Knowledge and Future Perspectives.

Authors:  Yannis Dimitroglou; Constantina Aggeli; Alexandra Alexopoulou; Sophie Mavrogeni; Dimitris Tousoulis
Journal:  J Clin Med       Date:  2019-12-03       Impact factor: 4.241

8.  Cardiac dysfunction related to cirrhosis.

Authors:  Odilson Marcos Silvestre; Alberto Queiroz Farias; Fernando Bacal
Journal:  Arq Bras Cardiol       Date:  2013-08       Impact factor: 2.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.